{
    "Clinical Trial ID": "NCT00110084",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Nab-paclitaxel/Gemcitabine",
        "  Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically or cytologically confirmed invasive breast cancer",
        "  - Clinical evidence of metastatic disease",
        "  + No bone metastases or other non-measurable disease as the only evidence of metastasis",
        "  Measurable disease, defined as at least 1 measurable lesion",
        "  - The following are considered non-measurable disease:",
        "  Small lesions (< 2 cm)",
        "  Bone lesions",
        "  Leptomeningeal disease",
        "  Ascites",
        "  Pleural or pericardial effusions",
        "  Inflammatory breast disease",
        "  Lymphangitis cutis or pulmonis",
        "  Abdominal masses that are not confirmed and followed by imaging techniques",
        "  Cystic lesions",
        "  HER2(human epidermal growth factor receptor 2)-positive disease allowed provided patient has received prior treatment with trastuzumab",
        "  No evidence of active brain metastasis, including leptomeningeal involvement",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  18 and over Sex",
        "  Female Menopausal status",
        "  Not specified Performance status",
        "  ECOG 0-1 Life expectancy",
        "  At least 12 weeks Hematopoietic",
        "  Absolute neutrophil count  1,500/mm^3",
        "  Platelet count  100,000/mm^3",
        "  Hemoglobin  9 g/dL Hepatic",
        "  AST and ALT  2.5 times upper limit of normal (ULN)",
        "  Bilirubin  1.5 times ULN Renal",
        "  Creatinine  1.5 mg/dL Other",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for 30 days after completion of study treatment",
        "  No pre-existing peripheral neuropathy > grade 1",
        "  No other clinically significant illness or significant medical condition that would preclude study participation",
        "  No history of allergy or hypersensitivity to paclitaxel protein-bound particles in an injectable suspension, paclitaxel, gemcitabine, albumin, drug product excipients, or agents that are chemically similar to study drugs",
        "  No serious medical risk factors involving any of the major organ systems that would preclude study participation",
        "  No active stage III or IV invasive non-breast malignancy within the past 5 years",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  See Disease Characteristics Chemotherapy",
        "  No more than 1 prior adjuvant chemotherapy regimen",
        "  No prior chemotherapy for metastatic disease",
        "  At least 6 months since prior adjuvant or neoadjuvant taxane",
        "  More than 2 weeks since prior cytotoxic chemotherapy",
        "  Prior neoadjuvant chemotherapy allowed",
        "  No other concurrent chemotherapy Endocrine therapy",
        "  Prior hormonal treatment as adjuvant therapy or for metastatic disease allowed Radiotherapy",
        "  Prior radiotherapy to target lesion allowed provided there is evidence of disease progression after completion of treatment",
        "  More than 2 weeks since prior radiotherapy, except radiotherapy to a non-target lesion only or single-dose palliative radiotherapy",
        "  No concurrent radiotherapy Surgery",
        "  Not specified Other",
        "  More than 2 weeks since prior investigational drugs",
        "  No concurrent participation in another clinical trial that is studying investigational procedures or therapies",
        "  Concurrent bisphosphonates (e.g., pamidronate or zoledronate) allowed for palliation of pain or lytic lesions from breast cancer"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Proportion of Patients With Confirmed Responses",
        "  Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 6 weeks apart.",
        "  Confirmed tumor response is at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions.",
        "  Time frame: Two consecutive evaluations at least 6 weeks apart",
        "Results 1: ",
        "  Arm/Group Title: Nab-paclitaxel/Gemcitabine",
        "  Arm/Group Description: Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle",
        "  Overall Number of Participants Analyzed: 50",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Confirmed response: 25",
        "Assessable: 50"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 11/50 (22.00%)",
        "  Anemia 3/50 (6.00%)",
        "  Febrile neutropenia 1/50 (2.00%)",
        "  Arrythmia 1/50 (2.00%)",
        "  Ileus 1/50 (2.00%)",
        "  Nausea 1/50 (2.00%)",
        "  Pain-Abdominal 1/50 (2.00%)",
        "  Vomiting 1/50 (2.00%)",
        "  Bronchial infection 1/50 (2.00%)",
        "  Sepsis 1/50 (2.00%)",
        "  Neutropenia 2/50 (4.00%)",
        "  Platelet count decreased 1/50 (2.00%)",
        "  Dehydration 1/50 (2.00%)",
        "  Arthralgia 1/50 (2.00%)"
    ]
}